Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,987 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06907017Recruiting
CorWave left heart pump first-in-human study
This trial tests a new left ventricular assist device (LVAD) for people with advanced heart failure who are not responding to standard treatments and are eligible for a heart transplant. The pump helps the heart circulate blood.
Sydney, New South WalesAges 18–75 - NCT06413615RecruitingPhase 2
Study of a new targeted drug for advanced solid tumors with HER2
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT06894797Recruiting
Chemo and radiation before and after surgery for rectal cancer
This study tests a sequence of chemotherapy and radiation before and after surgery for rectal cancer. It compares giving more chemo between the end of radiation and surgery (consolidation) versus giving some chemo before radiation starts (induction). The goal is to see which order works better.
BeijingAges 18–75 - NCT06141265RecruitingPhase 2
Niraparib maintenance after chemo and Avastin for advanced ovarian cancer
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
Beijing, Beijing MunicipalityAges 18–75 - NCT06855134Recruiting
Genome-guided treatment for advanced rare cancers
This trial compares treatment based on a detailed analysis of your tumor's genes (genome and transcriptome) with standard care. It aims to find better treatment options for people with advanced rare cancers that have not responded to previous therapy.
AugsburgAges 18 years+ - NCT06406426RecruitingPhase 2
New drug combo for advanced stomach cancer after first treatment fails
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06829355RecruitingPhase 2
Thymalfasin plus triple therapy for advanced colorectal cancer
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Beijing, ChinaAges 18–75 - NCT06212076RecruitingPhase 1/Phase 2
Testing IPG1094 for advanced solid tumors
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06230471RecruitingPhase 2
Pembrolizumab plus lenvatinib or chemo for advanced bile duct cancer
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
Beijing, Beijing MunicipalityAges 18–80 - NCT03503149Recruiting
Cancer patients get personalized tumor test guidance
This trial sets up a “molecular tumor board,” a team that reviews your tumor’s lab results and helps your doctor choose treatment options. It may help by making sense of tumor test findings so decisions are more personalized.
Tübingen, Baden-WurttembergAges Any age - NCT06359847RecruitingPhase 2
ST-1898 for advanced thyroid cancer that no longer responds to iodine therapy
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06239298RecruitingPhase 1/Phase 2
Testing ZG005 plus donafenib for advanced solid tumors
This trial tests two drugs, ZG005 and donafenib, together in people with advanced solid tumors that have not responded to other treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07622940RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Esophageal Cancer
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07417189RecruitingPhase 1/Phase 2
Study of ABSK141 for advanced solid tumors with KRAS G12D mutation
This study tests a new drug called ABSK141 for people with advanced solid tumors that have a specific mutation called KRAS G12D. It aims to see if the drug can shrink or control the cancer, and it has different phases for different groups of patients.
ShanghaiAges 18 years+ - NCT06250972RecruitingPhase 3
Radiotherapy for advanced pancreatic cancer with normal CA19-9 after chemo
This trial tests whether giving radiotherapy to the pancreas can help people with advanced pancreatic cancer whose CA19-9 level has dropped to normal after chemotherapy. It's for patients whose cancer is still locally advanced (hasn't spread to distant organs).
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06172205RecruitingPhase 3
Two ways to give chemo plus immunotherapy for advanced liver cancer
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
Guangzhou, GuangdongAges 18–75 - NCT06801665RecruitingPhase 2
Fecal transplant plus immunotherapy and chemotherapy for colon cancer with liver spread
This trial tests a combination of fecal microbiota transplant (FMT), an immunotherapy drug (QL1706), a targeted therapy (bevacizumab), and chemotherapy (XELOX) as a first treatment for advanced colon cancer that has spread to the liver. The goal is to see if this mix can help shrink tumors and improve outcomes.
ChangzhouAges 18–75 - NCT06798207RecruitingPhase 2
TQB2102 for advanced gynecologic cancers with HER2
This trial tests a new targeted drug, TQB2102, for women with advanced or recurrent gynecologic cancers that have some HER2 protein. It may be an option if your cancer has continued to grow after platinum chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06249256RecruitingEarly Phase 1
Fast CAR T cells for advanced solid tumors
This trial tests a new type of CAR-T cell therapy called Fast CAR T cells for people with advanced solid tumors. It is designed for patients whose tumors have certain markers (mesothelin and PD-L1) and who have not responded to or cannot tolerate standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06081907RecruitingPhase 1/Phase 2
IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Changsha, HunanAges 18–75 - NCT07401498Enrolling by invitation
Studying side effects of lymph node removal in lung cancer surgery
This trial looks at complications from removing lymph nodes during surgery for non-small cell lung cancer. It may help doctors understand how to make surgery safer.
UlyanovskAges 18 years+ - NCT06719362RecruitingPhase 1
Testing a new cancer drug alone and with other therapies
This trial tests an experimental drug called M3T01, either alone or combined with pembrolizumab and other standard treatments, for people with advanced solid tumors or glioblastoma. The goal is to see if it is safe and effective.
Portland, OregonAges 18 years+ - NCT07048743RecruitingPhase 2
Psilocybin therapy for caregivers of advanced cancer patients
This trial tests whether psilocybin-assisted therapy can help caregivers of people with advanced cancer who feel anxious or depressed. It focuses on improving emotional well-being and relationships.
Toronto, OntarioAges 18 years+ - NCT07267806RecruitingPhase 3
Camrelizumab and Apatinib with or without chemo for advanced liver cancer
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
Guangzhou, GuangdongAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,987 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.